(Q37880873)

24 August 2017

1 reference

title

CD30: an important new target in hematologic malignancies (English)

1 reference

24 August 2017

Yehuda E Deutsch

1

1 reference

24 August 2017

Tamar Tadmor

series ordinal

2

1 reference

24 August 2017

Eckhard R Podack

series ordinal

3

1 reference

24 August 2017

Joseph D Rosenblatt

series ordinal

4

1 reference

24 August 2017

27 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

52

1 reference

24 August 2017

9

1 reference

24 August 2017

1641-1654

1 reference

Standard therapy of advanced Hodgkin lymphoma

24 August 2017

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Salvage therapy in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

CD30-governor of memory T cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

TNF family ligands define niches for T cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

The survival of memory CD4+ T cells within the gut lamina propria requires OX40 and CD30 signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Mice deficient in OX40 and CD30 signals lack memory antibody responses because of deficient CD4 T cell memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

CD30 supports lung inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Opposite role for interleukin-4 and interferon-gamma on CD30 and lymphocyte activation gene-3 (LAG-3) expression by activated naive T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Serum levels of soluble CD30 in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Distinctive activated cellular subsets in colon from patients with Crohn's disease and ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

CD30 ligand in lymphoma patients with CD30+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Retracted: Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

The role of nuclear factor-kappa B in cytokine gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Production of a monoclonal antibody specific for Hodgkin and Sternberg–Reed cells of Hodgkin's disease and a subset of normal lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.574761

10.3109/10428194.2011.574761

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference